首页> 外文期刊>Breast care >Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy – German Experts’ Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019)
【24h】

Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy – German Experts’ Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019)

机译:治疗早期乳腺癌患者:证据,争议,共识:重点关注全身治疗 - 德国专家对第16届国际圣加仑共识会议的意见(维也纳2019年)

获取原文
           

摘要

A German working group of leading breast cancer experts have discussed the votes at the International St. Gallen Consensus Conference in Vienna for the treatment of primary breast cancer with regard to the German AGO (Ar­beitsgemeinschaft Gynäkologische Onkologie) recommendations for clinical practice in Germany. Three of the German breast cancer experts were also members of this year’s St. Gallen panel. Comparing the St. Gallen recommendations with the annually updated treatment recommendations of the Gynecological Oncology Working Group (AGO Mamma 2019) and the German S3 Guideline is useful, because the recommendations of the St. Gallen panel are based on expert opinions of different countries and disciplines. The focus of this article is on systemic therapy. The motto of this year’s 16th St. Gallen Consensus Conference was “Estimating the magnitude of clinical benefit.” The rationale behind this motto is that, for every treatment decision, a benefit-risk assessment must be taken into consideration for each patient.
机译:德国工作组领先的乳腺癌专家讨论了在维也纳国际圣加仑共识会议上的选票进行了德国前(ArbeitsGemeinschaftGynäkologischeOnkologie)在德国临床实践的建议。德国乳腺癌专家中的三个也是今年St. Gallen Panel的成员。比较ST. Gallen建议与每年更新的妇科肿瘤学工作组的治疗建议(前妈妈2019)和德国S3指南有用,因为St. Gallen小组的建议是基于不同国家和学科的专家意见。本文的重点是全身治疗。今年第16届圣加仑共识会议的座右铭是“估计临床效益的规模。”这座座右铭背后的理由是,对于每个治疗决定,必须为每位患者考虑益处风险评估。

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号